Loading
A phase 3 trial testing Pelabresib, now recruiting.
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib is a phase 3 interventional study registered as NCT06401356, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib. Planned enrolment is 50 participants (estimated). The study started in 2024-08-13 and primary completion is expected in 2027-06-02. No results have been posted on ClinicalTrials.gov.
Shares Pelabresib, Novartis.